{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:10:40Z","timestamp":1768003840676,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Erenumab is a fully human monoclonal antibody and a highly potent, first-in-class calcitonin gene-related peptide receptor inhibitor approved for migraine prevention in adults. Randomised, placebo-controlled trials show that erenumab treatment results in clinically meaningful responses, including significant reductions in monthly migraine days. Real-world evidence of the effectiveness of erenumab in patients with migraine is accruing, but gaps remain, and findings may vary according to region. We evaluated the usage patterns and effectiveness of erenumab in real-world settings in patients with migraine in the United Arab Emirates (UAE).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective, observational real-world study enrolled patients\u2009\u2265\u200918 years with migraine who were prescribed erenumab in the UAE. Data were collected at baseline and Months 1, 3 and 6. The primary study objective was to characterise usage patterns of erenumab in patients with chronic migraine (CM) or episodic migraine (EM) in real-world settings in the UAE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 166 patients, 124 (74.7%) were females. The mean (standard deviation) age at migraine onset was 29 (7.93) years. Seventy-one patients (42.8%) had CM and 95 (57.2%) had EM.<\/jats:p>\n                <jats:p>In the overall population, the mean monthly headache\/migraine days (MHD) at baseline was 15.7 (8.45) and mean change from baseline was\u2009\u2212\u20098.2 (8.83) at Month 1,\u2009\u2212\u200911.0 (9.15) at Month 3 and\u2009\u2212\u200911.3 (8.90) at Month 6. The mean change from baseline in monthly acute migraine-specific medication days (MSMD) was\u2009\u2212\u20099.0 (8.07) at Month 1,\u2009\u2212\u20099.7 (8.73) at Month 3 and\u2009\u2212\u200910.7 (8.95) at Month 6. At all time points, most patients achieved at least 50% reduction in MHD (80%\u201391%) and MSMD (84%\u201394%).<\/jats:p>\n                <jats:p>Similar reductions in MHD and MSMD and clinical benefit in CM or EM were seen with erenumab monotherapy or erenumab add-on therapy, with or without dose escalation and for treatment na\u00efve or\u2009\u2265\u20091 previous preventive treatment failures, with additional clinical benefit in the erenumab add-on therapy and dose escalation to 140 mg subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this real-world study on erenumab use in the UAE, patients prescribed erenumab achieved clinically meaningful reductions in MHD and MSMD at all assessed time points. Erenumab was well tolerated with no new safety events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02710-5","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T06:02:39Z","timestamp":1655359359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7513-5706","authenticated-orcid":false,"given":"Taoufik","family":"Alsaadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzan","family":"Noori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razmig","family":"Varakian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saly","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AbuBaker","family":"Almadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"2710_CR1","doi-asserted-by":"publisher","unstructured":"Agosti R. Migraine burden of disease: From the patient's experience to a socio-economic view. Headache. 2018;58 Suppl 1:17\u201332.\u00a0https:\/\/doi.org\/10.1111\/head.13301.","DOI":"10.1111\/head.13301"},{"key":"2710_CR2","doi-asserted-by":"publisher","unstructured":"Foster SA, Chen CC, Ding Y, Mason O, McGuiness CB, Morrow P, et al. Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database. J Med Econ.\u00a02020;23:1356\u201364.\u00a0https:\/\/doi.org\/10.1080\/13696998.2020.1814790.","DOI":"10.1080\/13696998.2020.1814790"},{"key":"2710_CR3","doi-asserted-by":"publisher","unstructured":"Collaborators GBDH. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study\u00a02016. Lancet Neurol. 2018;17:954\u201376.\u00a0https:\/\/doi.org\/10.1016\/S1474-4422(18)30322-3.","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"2710_CR4","doi-asserted-by":"publisher","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, Lifting The Burden: the Global Campaign against H. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21:137.\u00a0\u00a0https:\/\/doi.org\/10.1186\/s10194-020-01208-0.","DOI":"10.1186\/s10194-020-01208-0"},{"key":"2710_CR5","doi-asserted-by":"publisher","unstructured":"Benamer HT, Deleu D, Grosset D.\u00a0 Epidemiology of headache in Arab countries. J Headache Pain. 2010;11:1\u20133.\u00a0https:\/\/doi.org\/10.1007\/s10194-009-0173-8.","DOI":"10.1007\/s10194-009-0173-8"},{"key":"2710_CR6","doi-asserted-by":"publisher","unstructured":"Al-Hashel JY, Ahmed SF, Alroughani R. Burden of migraine in a Kuwaiti population: a door-to-door survey. J Headache Pain. 2017;18(1):105.\u00a0\u00a0https:\/\/doi.org\/10.1186\/s10194-017-0814-2.","DOI":"10.1186\/s10194-017-0814-2"},{"key":"2710_CR7","doi-asserted-by":"publisher","unstructured":"Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20:22\u201333.\u00a0https:\/\/doi.org\/10.18553\/jmcp.2014.20.1.22.","DOI":"10.18553\/jmcp.2014.20.1.22"},{"key":"2710_CR8","doi-asserted-by":"publisher","unstructured":"Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54\u201361.\u00a0https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00310.x.","DOI":"10.1046\/j.1468-2982.2002.00310.x"},{"key":"2710_CR9","doi-asserted-by":"publisher","unstructured":"Chiang CC, Schwedt TJ. 2020 Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants. Prog Brain Res.\u00a02020;255:143\u201370.\u00a0https:\/\/doi.org\/10.1016\/bs.pbr.2020.06.019.","DOI":"10.1016\/bs.pbr.2020.06.019"},{"key":"2710_CR10","unstructured":"Peters GL.\u00a0Migraine overview and summary of current and emerging treatment options. Am J Manag Care.\u00a02019;25:S23\u2013S34."},{"key":"2710_CR11","doi-asserted-by":"publisher","unstructured":"King CT, Gegg CV, Hu SN, Sen Lu H, Chan BM, Berry KA, et al. Discovery of the Migraine Prevention Therapeutic Aimovig (Erenumab), the First FDA-Approved Antibody against a G-Protein-Coupled Receptor.\u00a0 ACS Pharmacol Transl Sci.\u00a02019;2:485\u201390.\u00a0https:\/\/doi.org\/10.1021\/acsptsci.9b00061","DOI":"10.1021\/acsptsci.9b00061"},{"key":"2710_CR12","unstructured":"Aimovig\u00ae (erenumab-aooe) [prescribing Information].\u00a0Thousand Oaks: Amgen Inc.; 2020.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761077s000lbl.pdf.\u00a0Accessed 25 June 2021."},{"key":"2710_CR13","unstructured":"Aimovig\u00ae (erenumab-aooe) [summary of product characteristics]. Thousand Oaks: Amgen Inc.; 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aimovig-epar-product-information_en.pdf.\u00a0Accessed 25 June 2021."},{"key":"2710_CR14","doi-asserted-by":"publisher","unstructured":"Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123\u201332.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1705848.","DOI":"10.1056\/NEJMoa1705848"},{"key":"2710_CR15","doi-asserted-by":"publisher","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al.\u00a0\u00a0Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280\u20137.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0.","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"2710_CR16","doi-asserted-by":"publisher","unstructured":"Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:382\u201390.\u00a0https:\/\/doi.org\/10.1016\/S1474-4422(16)00019-3.","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"2710_CR17","doi-asserted-by":"publisher","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425\u201334.\u00a0https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2.","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"2710_CR18","doi-asserted-by":"publisher","unstructured":"Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Joshi S, et al. Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers. Neurol Ther.\u00a02021;10(1):293\u2013306.\u00a0https:\/\/doi.org\/10.1007\/s40120-021-00245-4","DOI":"10.1007\/s40120-021-00245-4"},{"key":"2710_CR19","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache S. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629\u2013808.https:\/\/doi.org\/10.1177\/0333102413485658.","DOI":"10.1177\/0333102413485658"},{"key":"2710_CR20","doi-asserted-by":"publisher","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Ozge A, et al. Migraine: epidemiology and systems of care. Lancet. 2021;397(10283):1485\u201395.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(20)32160-7.","DOI":"10.1016\/S0140-6736(20)32160-7"},{"key":"2710_CR21","doi-asserted-by":"publisher","unstructured":"Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, et al. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache.\u00a02021;61(9):1351\u201363.\u00a0https:\/\/doi.org\/10.1111\/head.14194.","DOI":"10.1111\/head.14194"},{"key":"2710_CR22","doi-asserted-by":"publisher","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, et al. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 2021;61(2):363\u201372.\u00a0https:\/\/doi.org\/10.1111\/head.14032.","DOI":"10.1111\/head.14032"},{"key":"2710_CR23","unstructured":"Gaul\u00a0C, Koch M, Baufeld C. Characterisation of patient and treatment profiles of migraine patients treated with erenumab in routine clinical practice: Interim results from the SPECTRE study.\u00a0J Headache Pain.\u00a02021;22 Suppl 1:112."},{"key":"2710_CR24","doi-asserted-by":"publisher","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21(1):61.https:\/\/doi.org\/10.1186\/s10194-020-01127-0.","DOI":"10.1186\/s10194-020-01127-0"},{"key":"2710_CR25","doi-asserted-by":"publisher","unstructured":"Straube A, Stude P, Gaul C, Schuh K, Koch M. Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany. J Headache Pain. 2021;22(1):133.\u00a0\u00a0https:\/\/doi.org\/10.1186\/s10194-021-01344-1.","DOI":"10.1186\/s10194-021-01344-1"},{"key":"2710_CR26","doi-asserted-by":"publisher","unstructured":"Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38:1611\u201321.\u00a0https:\/\/doi.org\/10.1177\/0333102418788347.","DOI":"10.1177\/0333102418788347"},{"key":"2710_CR27","doi-asserted-by":"publisher","unstructured":"Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F, et al. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2019;39:817\u201326. https:\/\/doi.org\/10.1177\/0333102419835459.","DOI":"10.1177\/0333102419835459"},{"key":"2710_CR28","doi-asserted-by":"publisher","unstructured":"AP Andreou M Fuccaro G Lambru 2020 The role of erenumab in the treatment of migraine. Ther Adv Neurol Disord.\u00a02020;13:1756286420927119.\u00a0https:\/\/doi.org\/10.1177\/1756286420927119.","DOI":"10.1177\/1756286420927119"},{"key":"2710_CR29","doi-asserted-by":"publisher","unstructured":"Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F, et al.\u00a0One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. Neurology. 2020;95:e469-e79.\u00a0https:\/\/doi.org\/10.1212\/WNL.0000000000010019.","DOI":"10.1212\/WNL.0000000000010019"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02710-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02710-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02710-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T06:02:43Z","timestamp":1655359363000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02710-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2710"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02710-5","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"28 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All relevant ethical, health authority, data privacy and site-specific approvals were obtained prior to the start of the study. The study was conducted in accordance with the principles of the Declaration of Helsinki.\u00a0Informed consent was obtained from patients before data collection. Depending on each site\u2019s local Institutional Review Board (IRB) regulations, a waiver of informed consent from the corresponding ethics committee was obtained. All authors were given access to the study data. The study protocol and ICF consent waiver has been reviewed and approval granted by the below mentioned ethics committees and HA: ACPN Institutional Review Board for ACPN site. Ministry of Health and Prevention for University of Sharjah site. University of Sharjah Ethics and Research Committee for University of Sharjah site. Dubai Scientific Research Ethics Committee for Rashid hospital site.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TA, SN and ABA have nothing to disclose. RV and SY are employees of Novartis Middle East FZE, Representative Office, Dubai, United Arab Emirates.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}